Regeneron Enters a ~$3B Multi-Year Manufacturing Agreement with FUJIFILM Diosynth Biotechnologies
Shots:
- FUJIFILM Diosynth Biotechnologies & Regeneron have entered into a 10-year manufacturing supply agreement, under which FUJIFILM will provide US-based manufacturing services for Regeneron
- As per the deal, FUJIFILM will receive ~$3B to manufacture biopharmaceuticals for Regeneron at its Holly Springs, North Carolina facility, which will begin operations in late 2025
- Holly Springs site is part of FUJIFILM’s global kojoX interconnected manufacturing network which offers standardized equipment, processes, & procedures across all sites to allow supply chain security & seamless tech transfers, with FUJIFILM bringing additional capacity online in 2025 & beyond
Ref: FUJIFILM Diosynth | Image: FUJIFILM Diosynth Biotechnologies & Regeneron
Related News:- Regeneron and Sanofi Report the US FDA’s Approval of Dupixent for Chronic Spontaneous Urticaria
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
